No pain, no gain goes the well-worn axiom. A stock market themed inverse can read: no gain, shareholder pain. You can currently apply the latter to Intercept Pharmaceuticals (ICPT). The small-cap biotech was hoping to gain the FDA’s nod of approval for its liver disease therapy, but there was only pain to endure, as the NDA was rejected. As a result, shares were sent tumbling by 40% on Monday June 29. So, what happened exactly? ICPT received a CRL from the FDA regarding its obeticholic acid (OCA) treatment in advanced-stage non-alcoholic steatohepatitis (NASH), due to a lack of evidence showing that the benefits of the treatment outweigh the potential risks. The FDA recommended that data from the ongoing Phase 3 REGENERATE study be further analyzed. NASH is a fatty liver disease, closely related to obesity, for which there are currently no specific drugs available. Due to the rising obesity rates, the market for NASH medications is expected to grow considerably over the next few years, with some estimates putting its worth at $35 billion. Intercept’s application was based on data from the treatment of over 1,700 NASH patients across 35 clinical trials. Management expects to schedule a meeting with the FDA in 2H20 to discuss how to move forward. Needham analyst Alan Carr expects the NDA to be resubmitted before the end of the year, and anticipates “the drug will be approved in the U.S. by mid-2021.” The analyst believes the rejection might have more to do with the current macro climate than with the data itself. Carr said, “We acknowledge the FDA clearly has some level of concern w/ OCA, however, we believe COVID-19 has played a role in disrupting and preventing completion of the review process. We await the outcome of the meeting with the FDA and assume resubmission by YE20. We still believe OCA will be approved in NASH, but have reduced our target due to launch delay.” That price target is slashed from $150 to $100, although the figure still implies hefty upside potential of 115%. Carr made no change to the rating, which remains a Buy. (To watch Carr’s track record, click here) Looking at the consensus breakdown, based on 6 Buys and 15 Holds, ICPT has a Moderate Buy consensus rating. With an average price target of $66.10, the analysts forecast possible upside of 42% over the next 12 months. (See Intercept price targets and analyst ratings on TipRanks)

from Yahoo Finance https://ift.tt/3ePcYff

We at Insider Monkey have gone over 821 13F filings that hedge funds and prominent investors are required to file by the SEC The 13F filings show the funds' and investors' portfolio positions as of March 31st, near the height of the coronavirus market crash. We are almost done with the second quarter. Investors decided […]

from Yahoo Finance https://ift.tt/3gcCXgK

Every investor in Agenus Inc. (NASDAQ:AGEN) should be aware of the most powerful shareholder groups. Institutions will…

from Yahoo Finance https://ift.tt/2BzP7lm

Yahoo Finance’s Adam Shapiro breaks down Thursday’s top trending headlines.

from Yahoo Finance https://ift.tt/3ioRDLX

Royal Dutch Shell is not ruling out moving its headquarters from the Netherlands to Britain, the oil company’s chief executive Ben van Beurden said in a Dutch newspaper interview published on Saturday. Anglo-Dutch consumer products giant Unilever said last month it plans to ditch its dual Anglo-Dutch legal structure and create a single entity in Britain. Van Beurden did not explicitly say Shell wants to move its headquarters, het Financieele Dagblad said.

from Yahoo Finance https://ift.tt/2YVGzOG

Luke Lloyd, a wealth advisor at Strategic Wealth Partners, joins Yahoo Finance to highlight how some Americans are using the COVID-19 pandemic as an opportunity to reset retirement goals.

from Yahoo Finance https://ift.tt/2VJ4wGJ

Those following along with T-Mobile US, Inc. (NASDAQ:TMUS) will no doubt be intrigued by the recent purchase of shares…

from Yahoo Finance https://ift.tt/3dYny28

from Yahoo Finance https://ift.tt/31FuXRH

After a better-than-expected jobs report, stocks finished the holiday-shortened trading week on a strong note. Let's look at a few top stock trades for the first full week of July. Top Stock Trades for Tomorrow No. 1: Nio (NIO) Click to EnlargeSource: Chart courtesy of StockCharts.com The $5 to $6 zone was set to be a tough one for Nio (NYSE:NIO), which topped out in this area in the first quarter of 2020. Previously, this zone had been support for the stock, before Nio slumped badly in 2019.In any regard, electric car stocks have serious momentum right now — led by Tesla (NASDAQ:TSLA), which has amassed a market cap north of $200 billion.InvestorPlace – Stock Market News, Stock Advice & Trading TipsIn any regard, Nio shares keep pressing higher, up more than 30% so far this week. Investors undoubtedly have their eyes fixed on $10. * 7 American Manufacturing Stocks to Buy Before Recovery Let's see how the stock does with the $10 to $10.50 zone, which historically, has been resistance. If it continues as resistance, let's see that a pullback into the $6 to $7 area is met with support. Above $10.50 and the all-time highs up at $13.80 are in play. Top Stock Trades for Tomorrow No. 2: DocuSign (DOCU) Click to EnlargeSource: Chart courtesy of StockCharts.com Man, there's nothing else to say about DocuSign (NASDAQ:DOCU) other than the stock has been a complete beast.The stock never even tested its 200-day moving average during the March selloff. While shares dipped 29.9% from the February high to March low — outperforming the S&P 500 and Nasdaq during that time — the rebound has been stunning. Shares are now up more than 200% from that low.However, DocuSign stock nearly tagged $200 on Thursday and may be running out of momentum.I want to see $180 hold as support. If it doesn't, it puts uptrend support (blue line) and the 20-day moving average in play. On a larger dip, see if $150 and/or the 50-day moving average buoy the stock, whichever comes into play first. Top Stock Trades for Tomorrow No. 3: JPMorgan (JPM) Click to EnlargeSource: Chart courtesy of StockCharts.com Despite the rebound in the overall market, the bank stocks have struggled. For its part, JPMorgan (NYSE:JPM) is doing its best not to break down. But that's not exactly bullish.Shares are below all of the stock's key moving averages and are well off the June high near $115. In fact, just from that level, shares are down about 20%.On the plus side, JPM stock has carved out a nice bottom over the past few sessions. If it holds, the stock will create another higher low, giving bulls something to chew on. For them to maintain momentum though, shares need to reclaim the 50-day moving average, and preferably, the $100 to $102.50 area.If it falls below uptrend support, $82.50 is in play. Top Trades for Tomorrow No. 4: Moderna (MRNA) Click to EnlargeSource: Chart courtesy of StockCharts.com Moderna (NASDAQ:MRNA) has been a tricky stock lately, but it has traded very technically.While shares slipped about 6% in Thursday's session and lost the 50-day moving average, support near $55 is holding up. If it continues to hold, see that MRNA stock reclaims the 50-day and 20-day moving averages.Above those levels puts recent range resistance in play, up near $67.50. Pushing above that could put a move up toward $80 on the table.If $55 support breaks, shares could see $45.Bret Kenwell is the manager and author of Future Blue Chips and is on Twitter @BretKenwell. As of this writing, Bret Kenwell did not hold a position in any of the aforementioned securities. More From InvestorPlace * Why Everyone Is Investing in 5G All WRONG * America's 1 Stock Picker Reveals His Next 1,000% Winner * Revolutionary Tech Behind 5G Rollout Is Being Pioneered By This 1 Company * Radical New Battery Could Dismantle Oil Markets The post 4 Top Stock Trades for Monday: NIO, DOCU, JPM, MRNA appeared first on InvestorPlace.

from Yahoo Finance https://ift.tt/2BBRfsS

Jul.02 — David Bloom, global head of foreign exchange strategy at HSBC, discusses the dollar’s status as the world’s reserve currency, why the euro isn’t going up or down, and why he’s still bearish on the pound. He speaks on “Bloomberg Markets: European Open.”

from Yahoo Finance https://ift.tt/38pQS0s